Ocuvia
Ophthalmology venture building for drug delivery and implant-based glaucoma therapies.
Company Overview
Snapshot
Founded in March 2026, Ocuvia operates with 1–10 employees and is currently in the Pre-Funding stage. The company is consolidating the activities of two BioLight Life Sciences portfolio companies, OphRx and ViSci, to streamline operations and fundraising.
Business overview
Ocuvia is an ophthalmology-focused venture formed by BioLight Life Sciences. The company consolidates the activities of OphRx, which develops eye-drop-based therapies to improve ocular drug delivery to the front of the eye and the retina, and ViSci, which is developing the D-EYE sub-conjunctival implant for controlled, sustained release of active ingredients for glaucoma. Ocuvia aims to streamline R&D, business development, and fundraising under a single management team, serving the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.
Log in to access full profile ›Company Intelligence Q&A
- What is Ocuvia's primary focus?
- Ocuvia is an ophthalmology-focused venture dedicated to drug delivery and implant-based glaucoma therapies.
- When was Ocuvia founded?
- Ocuvia was founded in March 2026.
- What is Ocuvia's current funding stage?
- Ocuvia is currently in the Pre-Funding stage, with BioLight examining a potential U.S. listing and capital raise during 2026.
- What is the strategic purpose behind Ocuvia's formation?
- Ocuvia was formed by BioLight Life Sciences to consolidate the activities of two portfolio companies, OphRx and ViSci, with the goal of streamlining R&D, business development, and fundraising under a single management team.
- What products or technologies does Ocuvia encompass?
- Ocuvia encompasses OphRx's platform for improving ocular drug delivery for eye-drop-based therapies and ViSci's D-EYE sub-conjunctival implant for controlled, sustained release of active ingredients for glaucoma.